| David Decktor, MD | |
|
555 N Duke St, Lancaster, PA 17602-2250 | |
| (717) 544-4900 | |
| (717) 544-5907 |
| Full Name | David Decktor |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 12 Years |
| Location | 555 N Duke St, Lancaster, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144589649 | NPI | - | NPPES |
| 103503140 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | MD463697 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lancaster General Hospital | Lancaster, PA | Hospital |
| Chester County Hospital | West chester, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lancaster Radiology Associates, Ltd. | 0648267526 | 38 |
| Mri Group, Llp | 3779554464 | 32 |
| University Of Penn - Medical Group | 6204730955 | 3031 |
News Archive
Aeolus Pharmaceuticals, Inc. announced today that after review of the Company's white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.
Even as vaccines against SARS-CoV-2 are being developed and administered at an unprecedented pace, treating this infection remains a challenge. To address this, researchers from China have used nanobodies (Nb) as a possible therapeutic approach. They reported Nb phage display libraries derived from four camels immunized with the SARS-CoV-2 spike RBD.
The Food and Drug Administration (FDA) in the United States says it is concerned that cough and cold products sold over the counter (OTC) are being irresponsibly used particularly with children under the age of two.
Scientists at the Dana-Farber/Children's Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment.
The Food and Drug Administration (FDA) in the United States has warned doctors about the dangers of a drug used to treat pain in cancer sufferers.
› Verified 5 days ago
| Entity Name | Lancaster Radiology Associates, Ltd. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669427100 PECOS PAC ID: 0648267526 Enrollment ID: O20040430000890 |
News Archive
Aeolus Pharmaceuticals, Inc. announced today that after review of the Company's white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.
Even as vaccines against SARS-CoV-2 are being developed and administered at an unprecedented pace, treating this infection remains a challenge. To address this, researchers from China have used nanobodies (Nb) as a possible therapeutic approach. They reported Nb phage display libraries derived from four camels immunized with the SARS-CoV-2 spike RBD.
The Food and Drug Administration (FDA) in the United States says it is concerned that cough and cold products sold over the counter (OTC) are being irresponsibly used particularly with children under the age of two.
Scientists at the Dana-Farber/Children's Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment.
The Food and Drug Administration (FDA) in the United States has warned doctors about the dangers of a drug used to treat pain in cancer sufferers.
› Verified 5 days ago
| Entity Name | Mri Group, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518129196 PECOS PAC ID: 3779554464 Enrollment ID: O20080729000341 |
News Archive
Aeolus Pharmaceuticals, Inc. announced today that after review of the Company's white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.
Even as vaccines against SARS-CoV-2 are being developed and administered at an unprecedented pace, treating this infection remains a challenge. To address this, researchers from China have used nanobodies (Nb) as a possible therapeutic approach. They reported Nb phage display libraries derived from four camels immunized with the SARS-CoV-2 spike RBD.
The Food and Drug Administration (FDA) in the United States says it is concerned that cough and cold products sold over the counter (OTC) are being irresponsibly used particularly with children under the age of two.
Scientists at the Dana-Farber/Children's Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment.
The Food and Drug Administration (FDA) in the United States has warned doctors about the dangers of a drug used to treat pain in cancer sufferers.
› Verified 5 days ago
| Entity Name | University Of Penn - Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235527342 PECOS PAC ID: 6204730955 Enrollment ID: O20141111000091 |
News Archive
Aeolus Pharmaceuticals, Inc. announced today that after review of the Company's white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.
Even as vaccines against SARS-CoV-2 are being developed and administered at an unprecedented pace, treating this infection remains a challenge. To address this, researchers from China have used nanobodies (Nb) as a possible therapeutic approach. They reported Nb phage display libraries derived from four camels immunized with the SARS-CoV-2 spike RBD.
The Food and Drug Administration (FDA) in the United States says it is concerned that cough and cold products sold over the counter (OTC) are being irresponsibly used particularly with children under the age of two.
Scientists at the Dana-Farber/Children's Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment.
The Food and Drug Administration (FDA) in the United States has warned doctors about the dangers of a drug used to treat pain in cancer sufferers.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Decktor, MD Po Box 4216, Lancaster, PA 17604-4216 Ph: (717) 394-6028 | David Decktor, MD 555 N Duke St, Lancaster, PA 17602-2250 Ph: (717) 544-4900 |
News Archive
Aeolus Pharmaceuticals, Inc. announced today that after review of the Company's white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.
Even as vaccines against SARS-CoV-2 are being developed and administered at an unprecedented pace, treating this infection remains a challenge. To address this, researchers from China have used nanobodies (Nb) as a possible therapeutic approach. They reported Nb phage display libraries derived from four camels immunized with the SARS-CoV-2 spike RBD.
The Food and Drug Administration (FDA) in the United States says it is concerned that cough and cold products sold over the counter (OTC) are being irresponsibly used particularly with children under the age of two.
Scientists at the Dana-Farber/Children's Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment.
The Food and Drug Administration (FDA) in the United States has warned doctors about the dangers of a drug used to treat pain in cancer sufferers.
› Verified 5 days ago
Dr. Matthew Jason Winfeld, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 555 N Duke St, Lancaster, PA 17602 Phone: 717-544-4900 Fax: 717-544-5907 | |
Patrick Weybright, Radiology Medicare: Accepting Medicare Assignments Practice Location: 555 N Duke St, Suite 3950, Lancaster, PA 17602 Phone: 717-299-4173 | |
Paul T Collura, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 250 College Ave, Lancaster, PA 17603 Phone: 717-735-8199 | |
Steven A Morales, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 555 N Duke St, Lancaster, PA 17602 Phone: 717-544-4900 Fax: 717-544-5907 | |
Dr. John Briguglio, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 555 N Duke St, Lancaster, PA 17602 Phone: 717-394-6028 Fax: 717-394-9223 | |
Alan Alexander, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 250 College Ave, Lancaster, PA 17603 Phone: 717-735-8188 | |
Dr. Margarita M Shultz, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1300 Millersville Pike, Lancaster, PA 17603 Phone: 717-393-5892 Fax: 717-393-3774 |